CHONG KUN DANG HOLDINGS CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 62,000 KRW | +0.32% |
|
+0.32% | +4.73% |
| Sales 2024 * | 896B 654M | Sales 2025 * | 914B 667M | Capitalization | 295B 215M |
|---|---|---|---|---|---|
| Net income 2024 * | 11B 8.03M | Net income 2025 * | 15B 10.95M | EV / Sales 2024 * | 0.33 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.32 x |
| P/E ratio 2024 * |
27.3
x | P/E ratio 2025 * |
20.4
x | Employees | 38 |
| Yield 2024 * |
2.26% | Yield 2025 * |
2.26% | Free-Float | 47.65% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.32% | ||
| 1 week | +0.32% | ||
| Current month | +3.85% | ||
| 1 month | -0.80% | ||
| 3 months | +5.80% | ||
| 6 months | +22.29% | ||
| Current year | +4.73% |
1 week
60 000.00
62 100.00
1 month
58 900.0064 300.00
Current year
57 200.0064 300.00
1 year
45 400.0064 300.00
3 years
45 400.00121 500.00
5 years
45 400.00156 000.00
10 years
41 700.00158 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sang-Yeon Hwang
CEO | Chief Executive Officer | 53 | - |
Jang-Won Choi
BRD | Director/Board Member | 62 | - |
Ja-Min Gu
BRD | Director/Board Member | 60 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jang-Han Lee
PRN | Corporate Officer/Principal | 71 | - |
Sang-Yeon Hwang
CEO | Chief Executive Officer | 53 | - |
Ja-Min Gu
BRD | Director/Board Member | 60 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 62,000 | +0.32% | 1,368 |
| 24-04-22 | 61,800 | +0.82% | 1,406 |
| 24-04-19 | 61,300 | +0.16% | 1,282 |
| 24-04-18 | 61,200 | +1.32% | 2,313 |
| 24-04-17 | 60,400 | -1.15% | 1,667 |
End-of-day quote Korea S.E., April 22, 2024
More quotes
CHONGKUNDANG HOLDINGS CORP., formerly Chong Kun Dang Pharmaceutical Corp., is a Korea-based company engaged in the investment business. Through its subsidiary, the Company provides pharmaceuticals, including remedies for high blood pressure and high cholesterol, immunosuppressive drugs, antitumor agents, antibiotics, remedies for erectile dysfunction and remedies for obesity. It also produces antitumor agents, antibiotics, digestives, circulation agents, respiratory agents, remedies for endocrine diseases, remedies for skin diseases, functional cosmetics and others, as well as pharmaceutical ingredients. On November 2, 2013, the Company divested its pharmaceutical business into a newly established wholly owned subsidiary. After the divestiture, the Company engages in the investment and holding business.
Sector
Food Processing
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
62,000
KRW
Average target price
63,000
KRW
Spread / Average Target
+1.61%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +4.73% | 213M | |
| +5.54% | 7.44B | |
| -2.62% | 7.21B | |
| +0.22% | 5.8B | |
| -8.57% | 3.65B | |
| -14.55% | 3.29B | |
| -15.31% | 1.16B | |
| +12.72% | 940M | |
| -39.38% | 907M | |
| -16.51% | 851M |
- Stock Market
- Equities
- A001630 Stock
